EPAD - European Prevention of Alzheimer's Dementia

European Prevention of Alzheimer's Dementia

- Newsletter November 2018 -

---

Welcome

Dear Friends and Colleagues,

EPAD had a fantastic summer, the cohort study reached a major milestone recruiting its 1,000th Research Participant on World Alzheimer Day and at present is over 1,100 Research Participants strong. For those of you who would like to follow recruitment more closely, EPAD’s WP3 has developed a great tool to do so: SEEPAD, check it out here. In addition, the EPAD Academy initiated its first exchange program and we saw the release of the first EPAD data set v500.0 which were presented at CTAD. Overall the EPAD scientific community has been very active of late, with 1 presentation and 2 posters at the IMI 10th Anniversary Scientific Symposium, 1 presentation and 5 posters at CTAD, and 2 presentations at the 28th Alzheimer Europe conference.

Unfortunately, it is not all good news for the Alzheimer field. At the start of the CTAD conference disappointing results were shared from several Phase 3 and one Phase 2 clinical study with beta-secretase (BACE) inhibitors that were in development for the treatment of Alzheimer’s disease (AD) targeting a broad spectrum of the AD population ranging from people with preclinical AD, to mild cognitive impairment (MCI) and mild-to-moderate dementia. We already knew that development of Merck’s verubecestat, Eli Lilly’s LY3202626 and Janssen’s atabecestat were stopped, the first two for lack of efficacy, atabecestat because of its unfavorable benefit-risk profile (i.e. increase in liver enzymes). At CTAD additional results were presented that indicated treatment with these compounds might also have resulted in worsening on cognitive measures. You can learn more in the following CTAD press release “IS THERE A ROLE FOR BACE INHIBITION IN ALZHEIMER’S TREATMENT?” Although it is still too early to conclude whether these effects are specific to these BACE inhibitors or involve the entire class, one thing is clear and that is that these results point to the need for clinical trial platforms such as EPAD. Both in the verubecestat and atabecestat studies the decline in cognitive function became apparent already after 3-6 months of treatment. However, because of the design of these studies this decline went undetected until the data were analyzed once the studies were stopped. In EPAD, because all data -including the cognitive data- are analyzed and reviewed every three months such an effect would have been noticed much earlier. Furthermore, these results once more emphasize the need for doing proof-of-concept studies before entering large scale Phase 3 studies involving many patients.

Many companies start realizing this, which also shows in EPAD’s well-stocked virtual pipeline. The negotiations with the first intervention owner are progressing well and we are hopeful that we will be able to start the first PoC appendix in the summer of 2019 (more news to follow soon). In addition, the clinical candidate selection committee has two more interventions lined up with a scheduled start late 2019 to early 2020 and is already discussing with other potential intervention owners whose compounds are not yet PoC ready but will be in 2021 or 2022.

To close I would already like to draw your attention to the EPAD General Assembly which will be organized and hosted by Prof. Frisoni and his team in Geneva from May 15-17. If you have not done so already, I suggest you already block you calendars so you do not miss out on the must attend EPAD event of the year.

So far 2018 has been a great year for EPAD, and thanks to your continued dedication and ceaseless efforts 2019 has the potential to be even better. I realize I have said it before, but in my view, it cannot be repeated enough, thank you for all you have done and continue to do for EPAD as we prepare to start the PoC in 2019.

This electronic newsletter will be published quarterly and be accessible via the EPAD website (http://ep-ad.org/) and inform the Alzheimer’s community on EPAD’s main achievements, upcoming events as well as allow you to meet the scientists who make it all happen.

We hope you enjoy this issue of the EPAD newsletter! Happy Reading!

Serge Van der Geyten

EPAD Coordinator

---
EPAD passes the mark of 1,000 participants for its Longitudinal Cohort Study

Q3 2018 Highlights

EPAD passes the mark of 1,000 participants for its Longitudinal Cohort Study

The members of the EPAD initiative are glad to announce that its Longitudinal Cohort Study has recruited its 1,000th participant at the University of Oxford (UK) this 21st September on World Alzheimer's Day. EPAD is one of the world leading dementia prevention studies, led from the University of Edinburgh. It is a Europe-wide collaboration aiming to improve the understanding of …

Read more.

---
EPAD Scotland inaugural meeting sees progress and participants at heart of agenda

The Story behind the Picture

EPAD Scotland inaugural meeting sees progress and participants at heart of agenda

On 29 August, EPAD’s Scottish team were lucky enough to visit the stunning University of Aberdeen campus for the inaugural EPAD Scotland conference. Held in the historic heart of the University, almost 80 delegates including participants, site staff and the wider Scottish EPAD team were treated to an uplifting and informative day of talks, as well as some unseasonal sunshine …

Read more.

---

Meet the EPAD team

Interview with Kristy Draper

Interview with Kristy Draper

What is your current role in EPAD? I am the Global Trial Lead for the Proof of Concept Trial working in the Chief Investigator’s office at the University of Edinburgh.  In this role I am responsible for bringing together the EPAD team at the University and IQVIA to work with intervention owners who wish to test their compound using the …

Read more.

Interview with Andy Bolan

Interview with Andy Bolan

What is your current role in EPAD? I am a brand-new member of the EPAD work package six. Having joined the Alzheimer’s team at Biogen in May 2018, the EPAD work was highlighted as a key coalition to join and support from a communications and advocacy perspective. I bring to the team over six years of experience in working with …

Read more.

---
EPAD design

EPAD presents @

• Partnerships in Clinical Trials Europe, 27-29 November, Barcelona (Spain)

• AETIONOMY final symposium, 29-30 November, Bonn (Germany)

---

Quarterly Quote

"Where there’s life, there’s hope"

 Stephen Hawking -

---